+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Recent Developments across Biotechnology Sector

  • ID: 4327571
  • Report
  • June 2017
  • Region: Global
  • 15 pages
  • Frost & Sullivan
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
This edition of the Genetic Technology TOE depicts trends across biotechnology. Opiod addiction tests that have been approved, companies developing companion diagnostics kits, novel genetic tests, and potential drug-based treatments are illustrated through the most recent innovations. The corresponding clinical trial scenario for CAR T Cell is depicted along with industry interactions.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Note: Product cover images may vary from those shown
2 of 2
Innovations in Biotechnology Genetics Solutions
  • Opioid Addiction Drug with FDA Approval Likely to Be Available in Different Administration Methods
  • Immunotherapy Companies Developing Companion Diagnostic Services
  • Drug Therapeutics to Improve Women’s Reproductive Health
  • Genetic Test Determines 70 Genetic Markers to Provide Personalized Skin Care Solutions
CAR T Cell Clinical Trials and Industry Interactions
  • Clinical Trial Overview Involving Chimeric Antigen Receptors (CAR)-T Cells Worldwide (2007-2016)
  • Industry Interactions
Note: Product cover images may vary from those shown
3 of 2